<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04415047</url>
  </required_header>
  <id_info>
    <org_study_id>P02C320</org_study_id>
    <nct_id>NCT04415047</nct_id>
  </id_info>
  <brief_title>THE ALIGN-AR PIVOTAL TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study</brief_title>
  <acronym>ALIGN-AR</acronym>
  <official_title>A Study to Assess Safety and Probable Benefit of the Transfemoral JenaValve Pericardial TAVR System in the Treatment of High Surgical Risk Patients With Symptomatic, Severe Aortic Regurgitation (AR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JenaValve Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JenaValve Technology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect information about treatment for symptomatic severe Aortic Regurgitation (AR),
      which affects the aortic valve in the heart. Aortic regurgitation is a condition where aortic
      valve in the heart does not close tightly and allows some blood to leak back into the heart
      chamber. Symptoms of aortic regurgitation may include fatigue and shortness of breath. The
      preferred treatment for severe aortic regurgitation is aortic valve replacement surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the use of TAVR (Transcatheter Aortic Valve Replacement), which is a
      minimally invasive procedure designed to replace the aortic valve inside the heart. In this
      study, TAVR will be performed using the JenaValve Pericardial TAVR System, which is intended
      to help treat symptomatic severe aortic regurgitation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality at 6 Months</measure>
    <time_frame>6 Months</time_frame>
    <description>All-Cause mortality within the first 6 months post index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>At 30 days</time_frame>
    <description>Absence of procedural mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-Procedural Myocardial Infarction</measure>
    <time_frame>At ≤72hr after the index procedure):</time_frame>
    <description>Peri-procedural and spontaneous myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke-Free Survival</measure>
    <time_frame>At 30 days and 1 year</time_frame>
    <description>Disabling or non-disabling stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding &amp; Vascular Complications</measure>
    <time_frame>At 30 days</time_frame>
    <description>Major and minor bleeding</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aortic Regurgitation</condition>
  <condition>Aortic Valve Disease</condition>
  <arm_group>
    <arm_group_label>Transcatheter Aortic Valve Replacement (TAVR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAVR with JenaValve Pericardial Valve and Delivery System Intervention Device: JenaValve Pericardial TAVR System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JenaValve Pericardial TAVR System</intervention_name>
    <description>TAVR with JenaValve Pericardial Valve and Delivery System</description>
    <arm_group_label>Transcatheter Aortic Valve Replacement (TAVR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with severe aortic regurgitation (AR).

          -  Patient at high risk for open surgical valve replacement

          -  Patient symptomatic according to NYHA functional class II or higher

          -  The study patient has been informed of the nature of the study, agrees to its
             provisions and has provided written informed consent as approved by the Institutional
             Review Board (IRB)/ Ethics Committee (EC) of the respective clinical site.

        Exclusion Criteria:

          -  Congenital uni or bicuspid aortic valve morphology

          -  Previous prosthetic aortic valve (bioprosthesis or mechanical) implant

          -  Endocarditis or other active infection

          -  Need for urgent or emergent TAVR procedure for any reason

          -  Cardiogenic shock or hemodynamic instability requiring inotropic support or
             ventricular assist device

          -  Severe mitral regurgitation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin B. Leon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York-Presbyterian/ Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torsten P. Vahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York-Presbyterian/ Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinod H. Thourani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Piedmont Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephan Baldus, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum der Universität zu Köln</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vinny Podichetty, Vice President: Clinical &amp; Med Affairs</last_name>
    <phone>949-396-7510</phone>
    <email>podichetty@jenavalve.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitch Gheorghiu</last_name>
      <phone>310-423-6152</phone>
      <email>Mitch.Gheorghiu@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Raj Makkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center Research Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milena Ferreira</last_name>
      <phone>415-600-5707</phone>
      <email>ferreiml@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>David V. Daniels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erin Collins</last_name>
      <phone>202-877-6622</phone>
      <email>Erin.C.Collins@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Ron Waksman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimi Wang</last_name>
      <phone>404-605-5699</phone>
      <email>kimi.wang@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Christopher U. Meduri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Charles</last_name>
      <phone>678-778-7706</phone>
      <email>echarl2@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Adam B. Greenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Oakley</last_name>
      <phone>734-232-9051</phone>
      <email>joakley@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Stanley J. Chetcuti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers State University</name>
      <address>
        <city>Piscataway</city>
        <state>New Jersey</state>
        <zip>08854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susette Coyle</last_name>
      <phone>732-235-8142</phone>
      <email>coylesu@rwjms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Mark J. Russo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York-Presbyterian/ Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Borden</last_name>
      <phone>212-342-5129</phone>
      <email>sb1097@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Torsten P. Vahl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Necole Kell</last_name>
      <phone>469-817-4720</phone>
      <email>necole.kell@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Molly Szerlip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kate Jordan</last_name>
      <phone>206-616-6768</phone>
      <email>jordank1@cardiology.washington.edu</email>
    </contact>
    <investigator>
      <last_name>James McCabe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 31, 2020</study_first_submitted>
  <study_first_submitted_qc>May 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>July 11, 2020</last_update_submitted>
  <last_update_submitted_qc>July 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

